

Godrej Agrovet

Estimate change	
TP change	
Rating change	

Bloomberg	GOAGRO IN
Equity Shares (m)	192
M.Cap.(INRb)/(USDb)	128.4 / 1.5
52-Week Range (INR)	878 / 476
1, 6, 12 Rel. Per (%)	-16/-9/12
12M Avg Val (INR M)	288

Financials & Valuations (INR b)

Y/E MARCH	2025	2026E	2027E
Sales	93.8	109.0	119.4
EBITDA	8.2	10.0	12.1
Adj. PAT	4.3	5.7	7.2
EBITDA Margin (%)	8.7	9.1	10.1
Cons. Adj. EPS (INR)	22.4	29.5	37.6
EPS Gr. (%)	19.5	31.6	27.6
BV/Sh. (INR)	124	95	132
Ratios			
Net D:E	0.6	1.1	0.6
RoE (%)	17.5	27.0	33.2
RoCE (%)	11.7	15.4	18.6
Payout (%)	46.9	35.6	-
Valuations			
P/E (x)	29.8	22.6	17.7
EV/EBITDA (x)	17.6	15.1	11.9
Div. Yield (%)	1.6	1.6	-
FCF Yield (%)	5.9	3.7	4.5

Shareholding pattern (%)

	Mar-25	Dec-24	Mar-24
Promoter	67.6	67.6	74.1
DII	9.2	10.4	12.9
FII	3.8	2.9	1.7
Others	19.5	19.1	11.4

Note: FII includes depository receipts

CMP: INR668

TP: INR840 (+26%)

Buy

Operating performance a mixed bag, below our est.

- Godrej Agrovet (GOAGRO) reported a subdued operating performance (EBIT marginally down 2% YoY) in 4QFY25, primarily due to a sharp 68%/66% YoY decline in Dairy/Poultry EBIT, while Animal Feed (AF)/Crop Protection (CP) EBIT dipped ~4%/2% YoY. These were partly offset by Palm Oil EBIT, which doubled YoY, fueled by higher realization.
- Revenue remained flat YoY mainly due to a significant decline in AF/Poultry business revenue (volume-led decline), offset by higher revenue in Palm Oil (realization-led growth).
- Management has guided to achieve a revenue growth of ~16-18% in FY26, led by CP, AF, and Astec. Similar growth in EBITDA is anticipated, largely led by lower losses in the Astec business and improving margins in Palm Oil. However, we factor in lower-than-expected performance in 4QFY25 and reduce our FY26E EBITDA by 8%, while largely maintaining our FY27E EBITDA. **We reiterate our BUY rating on the stock with an SOTP-based TP of INR840.**

Higher input costs hurt margins of the Dairy and Poultry business

- Consolidated revenue remained flat YoY at INR21.3b (est. in-line). EBITDA margins also remained flat at 6.9% (est. 9%), led by flattish gross margins at 25.9%. EBITDA stood at INR1.5b, flat YoY (est. INR2b). Adjusted PAT grew 24% YoY to INR708m (est. of INR1.1b).
- AF:** Revenue reduced by 4% YoY to INR11.4b, led by a volume growth of ~2% YoY to 370kmt. Margins remained flat, primarily led by a decline in average realization.
- Palm Oil:** Revenue grew ~30% YoY to INR2.4b, led by higher realizations in crude palm oil (CPO) and palm kernel oil (PKO), as realizations improved ~55% and ~72%, respectively. FFB arrivals rose 10% YoY, resulting in an EBIT margin expansion of 260bp YoY to 7.5% and an EBIT growth of ~2x YoY to INR184m.
- CP:** Consolidated CP revenue increased 6.4% YoY to ~INR2.7b led by a 28.6% YoY growth in standalone CP revenue. Standalone CP segment results witnessed strong growth in 4Q on account of higher volumes of in-house categories of products. Astec witnessed a 13% YoY dip in revenue to INR1.17b due to lower CDMO business. Consolidated CP EBIT declined 2.4% YoY to INR457m, led by an EBIT loss of INR83m in Astec, offset by a 32% YoY rise in standalone CP EBIT to INR540m.
- The **Dairy** business dipped ~2% YoY to INR3.8b, while EBIT declined ~68% YoY to INR66m, led by an increase in procurement prices. **Poultry and Processed Food** business revenue declined ~17.4% YoY to INR1.8b, primarily due to lower volumes in the live bird business, while EBIT stood at INR41m (down 65.9% YoY) and EBIT margin contracted 323bp YoY to ~2.3%.
- In FY25, GOAGRO reported a revenue decline of 2% to INR93.8b, while EBITDA/Adj. PAT grew 16%/20% to INR8.2b/INR4.3b.

Research Analyst - Sumant Kumar (Sumant.Kumar@MotilalOswal.com) | **Meet Jain** (Meet.Jain@MotilalOswal.com)

Research Analyst - Nirvik Saini (Nirvik.Saini@MotilalOswal.com) | **Yash Darak** (Yash.Darak@MotilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.

Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

Highlights from the management commentary

- **Crop protection (standalone):** The management is guiding over 30% revenue growth and margins led by the launch of new molecules and a good macro environment. One in-licensing product is slated for launch in FY26. Five molecules and one to two mixtures (sourced from Japan) are currently under development. Most of the launches are planned over the next 8–10 quarters, primarily in FY27.
- **Palm Oil:** Crude Palm Oil (CPO) and Palm Kernel Oil (PKO) prices are moderating, with CPO prices now at INR115,000–118,000/MT, down from INR130,000/MT. In contrast, PKO prices remain strong at INR215,000–230,000/MT, offering competitiveness in coconut oil (positive for margins). Management is expecting a healthy FFB arrival volume growth of ~18% in FY26.
- **Astec:** The management is guiding over 35% revenue CAGR for the next couple of years, largely led by the CDMO business. The CDMO business is recovering and is expected to contribute 70–75% of total Astec revenue by FY26 (vs. ~60% currently). The enterprise business is coming out of the woods, with volume-led improvement expected going forward (largely in old molecules).

Valuation and view

- GOAGRO reported flat revenue growth in FY25, but margins expanded 140bp due to strategic initiatives by the management. Going forward, with an improving outlook for Astec and volume-led growth in CP standalone, AF, and palm oil, we expect the company to see healthy revenue growth in the near term. Margins are anticipated to further expand going forward, fueled by continued strategic interventions across segments and recovery in Astec.
- We expect a revenue/EBITDA/Adj. PAT CAGR of 13%/22%/30% over FY25-27. We reiterate our BUY rating on the stock with an SOTP-based TP of INR840.

Y/E March	Consolidated - Quarterly Earnings Model								(INR m)		
	FY24				FY25				FY24	FY25E	FY25E
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	4QE	Var (%)	
Gross Sales	25,102	25,709	23,452	21,343	23,508	24,488	24,496	21,336	95,606	93,828	22,189
YoY Change (%)	0.0	5.1	0.9	1.9	-6.4	-4.8	4.5	0.0	2.0	-1.9	4.0
Total Expenditure	23,173	23,694	21,861	19,863	21,246	22,254	22,296	19,870	88,591	85,666	20,150
EBITDA	1,929	2,014	1,591	1,480	2,261	2,234	2,200	1,467	7,015	8,162	2,039
Margins (%)	7.7	7.8	6.8	6.9	9.6	9.1	9.0	6.9	7.3	8.7	9.2
Depreciation	528	529	530	556	546	583	567	565	2,143	2,261	600
Interest	295	279	251	254	302	398	345	289	1,079	1,334	320
Other Income	115	112	84	102	92	126	87	130	413	435	149
PBT before EO expense	1,222	1,318	894	772	1,506	1,379	1,376	742	4,206	5,002	1,268
Extra-Ord expense	0	0	0	0	0	0	0	0	0	0	0
PBT	1,222	1,318	894	772	1,506	1,379	1,376	742	4,206	5,002	1,268
Tax	353	369	191	220	345	541	414	204	1,133	1,504	319
Rate (%)	28.9	28.0	21.3	28.5	22.9	39.3	30.1	27.5	26.9	30.1	25.2
Minority Interest & Profit/Loss of Asso. Cos.	-185	-104	-215	-19	-190	-286	-153	-170	-523	-799	-118
Reported PAT	1,053	1,053	918	571	1,352	1,123	1,115	708	3,596	4,297	1,067
Adj PAT	1,053	1,053	918	571	1,352	1,123	1,115	708	3,596	4,297	1,067
YoY Change (%)	27.3	46.7	43.5	84.2	28.3	6.7	21.4	23.9	44.1	19.5	86.7
Margins (%)	4.2	4.1	3.9	2.7	5.7	4.6	4.6	3.3	3.8	4.6	4.8

Key Performance Indicators

Y/E March	FY24				FY25				FY24	FY25
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q		
Segment Revenue Gr. (%)										
Animal Feed (AF)	3.1	1.8	1.5	-2.3	-10.1	-3.0	-1.3	-3.6	1.0	(4.5)
Palm Oil	-39.9	10.5	-2.2	28.3	12.4	-1.5	37.6	30.1	(6.0)	17.3
Crop Protection	3.8	2.3	3.1	5.1	-4.6	-21.7	-13.1	6.4	3.5	(9.1)
Dairy	7.9	8.1	5.3	-1.7	1.0	3.2	1.0	-2.0	4.8	0.8
Segment EBIT Margin (%)										
Animal Feed	4.2	4.6	4.0	5.7	6.8	5.9	6.0	5.7	4.6	6.1
Palm Oil	12.1	15.4	19.0	4.9	9.2	16.7	23.7	7.5	14.2	16.2
Crop Protection	20.9	17.1	11.1	18.4	23.8	18.6	6.2	16.9	17.5	17.7
Dairy	-0.6	0.8	2.8	5.2	4.3	2.1	2.5	1.7	2.0	2.7
AF Volumes (000'MT)	374	372	390	362	346	362	397	370	945	1,013
AF Realization (INR/kg)	34.3	33.4	33.1	32.8	33.4	33.3	32.1	31.0	33.4	32.4
Cost Break-up										
RM Cost (% of sales)	75.8	76.3	76.3	74.5	73.2	74.4	74.4	74.1	75.8	74.0
Staff Cost (% of sales)	5.4	5.5	5.2	6.6	6.0	5.0	5.7	6.1	5.6	5.7
Other Cost (% of sales)	11.1	10.3	11.7	12.0	11.2	11.5	10.9	12.9	11.3	11.6
Gross Margins (%)	24.2	23.7	23.7	25.5	26.8	25.6	25.6	25.9	24.2	26.0
EBITDA Margins (%)	7.7	7.8	6.8	6.9	9.6	9.1	9.0	6.9	7.3	8.7
EBIT Margins (%)	5.6	5.8	4.5	4.3	7.3	6.7	6.7	4.2	5.1	6.3




Key exhibits
Exhibit 1: Consolidated revenue trend

Exhibit 2: Consolidated EBITDA trend

Exhibit 3: Consolidated adjusted PAT trend


Exhibit 4: Animal Feed business

Particulars	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25
Volume (MT)	3,63,914	3,74,215	3,72,212	3,90,472	3,62,116	3,45,948	3,61,597	3,97,498	3,70,104
Growth (%)	4.7	6.0	4.3	1.8	-0.5	-7.6	-2.9	1.8	2.2
Revenue (INR m)	12,180	12,847	12,420	12,914	11,896	11,554	12,054	12,742	11,463
Growth (%)	10.2	3.1	1.8	1.5	-2.3	-10.1	-3.0	-1.3	-3.6
EBIT (INR m)	445	539.8	570.6	522.6	678.7	781.2	706.3	769.2	654.4
Margin (%)	3.7	4.2	4.6	4.0	5.7	6.8	5.9	6.0	5.7
Growth (%)	-26.1	120.4	15.8	-9.6	52.5	44.7	23.8	47.2	-3.6

Exhibit 5: Consolidated Crop Protection business

Particulars	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25
Revenue (INR m)	2,421	3,819	3,790	2,225	2,544	3,645	2,967	1,934	2,708
Growth (%)	-31.4	3.8	2.3	3.1	5.1	-4.6	-21.7	-13.1	6.4
EBIT (INR m)	132	799	649	248	468	868	551	119	457
Margin (%)	5.5	20.9	17.1	11.1	18.4	23.8	18.6	6.2	16.9
Growth (%)	-84.1	78.5	10.2	188.6	253.4	8.5	-15.1	-52.0	-2.4

Exhibit 6: Standalone Crop Protection business

Particulars	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25
Revenue (INR m)	1,280	2,640	2,600	1,720	1,190	3,140	1,980	990	1,530
Growth (%)	21.8	33.3	52.6	73.4	-7.0	18.9	-23.8	-42.4	28.6
EBIT (INR m)	140	850	770	520	410	1,420	850	270	540
Margin (%)	10.9	32.2	29.6	30.2	34.5	45.2	42.9	27.3	35.3
Growth (%)	-34.0	225.8	148.5	1429.4	192.9	67.0	10.3	-48.1	31.7

Exhibit 7: Astec Lifesciences business

Particulars	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25
Revenue (INR m)	1,141	1,179	1,190	505	1,354	505	987	944	1,178
Growth (%)	-53.9	-30.6	-40.5	-56.7	18.7	-57.2	-17.0	87.1	-13.0
EBITDA (INR m)	80	50	-24	-170	150	-453	-177	-38	63
Margin (%)	7.0	4.2	-2.0	-33.7	11.1	-89.7	-17.9	-4.0	5.3
Growth (%)	-88.9	-82.3	-106.4	-206.8	87.5	-1006.0	643.8	-77.6	-58.0

Exhibit 8: Palm Oil business

Particulars	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25
Revenue (INR m)	1,461	2,317	4,474	3,545	1,875	2,604	4,407	4,877	2,439
Growth (%)	-22.8	-39.9	10.5	-2.2	28.3	12.4	-1.5	37.6	30.1
EBIT (INR m)	183	280	687	672	92	241	736	1,154	184
Margin (%)	12.5	12.1	15.4	19.0	4.9	9.2	16.7	23.7	7.5
Growth (%)	-44.5	-67.3	4.8	-15.4	-49.9	-14.1	7.1	71.7	100.0

Exhibit 9: Dairy business

Particulars	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25
Revenue (INR m)	3,991	4,245	3,901	3,662	3,921	4,286	4,027	3,698	3,842
Growth (%)	18.5	7.9	8.1	5.3	-1.7	1.0	3.2	1.0	-2.0
EBITDA (INR m)	47	47	47	47	47	47	47	47	47
Margin (%)	1.2	1.1	1.2	1.3	1.2	1.1	1.2	1.3	1.2
Growth (%)	2.2	2.2	2.2	2.2	0.0	0.0	0.0	0.0	0.0
EBIT (INR m)	-82.9	-25	29.3	102.2	203.4	185.3	84.3	92.6	66.1
Margin (%)	-2.1	-0.6	0.8	2.8	5.2	4.3	2.1	2.5	1.7

Exhibit 10: Poultry and Processed Foods business

Particulars	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25
Revenue (INR m)	2,461	3,102	2,369	2,229	2,164	2,342	1,973	2,155	1,788
Growth (%)	21.7	25.0	3.7	-20.5	-12.1	-24.5	-16.7	-3.3	-17.4
EBIT (INR m)	-32	269	149	-73	119	193	5	65	41
Margin (%)	-1.3	8.7	6.3	-3.3	5.5	8.2	0.3	3.0	2.3
Growth (%)	NA	NA	NA	NA	NA	-28.4	-96.6	-188.9	-65.9

Source: Company, MOFSL



Highlights from the management commentary

Astec

- The phase has been challenging for the **enterprise segment**, primarily due to pricing pressure, and is now behind. A recovery is expected, driven largely by volumes.
- Certain molecules are expected to deliver robust volume growth of 20–30%, though a few will remain under stress. Gross margins are guided to remain in the range of 20–23%. Approximately 90% of the growth will be driven by existing molecules.
- The **CDMO business** is gradually recovering. CDMO is expected to contribute 70–75% of total revenue by FY26 (vs ~60% currently). The company will focus heavily on scaling the CDMO segment over the next 2–3 years. CDMO activity generally ramps up in H2, however in H2FY25, order cancellations led to a revenue decline in this segment
- CDMO business is expected to grow by ~35% annually for FY26. A new product launch is planned, complementing growth from existing molecules.
- For Astec, PAT loss is expected to reduce to half of FY25 levels, with positive EBITDA projected.
- The company has not planned any capex over Astec in the near term.

Crop protection (standalone)

- Channel placement is strong, supported by expectations of a normal monsoon. Retail-level dispatches are progressing well, indicating a healthy season and strong volumes. EBIT margins, currently around 40%, are expected to normalize to ~30%+ in FY26 as current levels are unsustainable
- One in-licensing product is slated for launch in FY26. Five molecules and one to two mixtures (sourced from Japan) are currently in development. These have peak revenue potential of USD10–20m each. Most launches are planned over the next 8–10 quarters, primarily in FY27.
- The company is expanding into new crops and geographies to mitigate concentration risk. Focus areas now include the Western and Central regions, along with an increased presence in vegetable crops, aiding geographical and crop diversification.

Dairy

- Lower margins in FY25 were partly due to higher marketing spending (~INR60m in 4QFY25) for Value-Added Products (VAP). Actor Rana Daggubati was roped in as a brand ambassador to strengthen brand visibility.
- The saliency of VAP is expected to cross 40% in FY26. Price hikes of 4–5% (and up to 10% in certain areas) have been implemented in case of VAP. However, such products form only 10 – 12% of the portfolio.
- Direct milk procurement has exceeded 60% and is targeted to reach 70%, reducing dependency on chilling infrastructure by ~50%.
- EBITDA margins are expected to grow to 6–7% (from ~5% currently) in FY26.

Palm Oil

- Crude Palm Oil (CPO) and Palm Kernel Oil (PKO) prices increased due to higher import duties. Prices have now corrected: CPO is at INR 115,000–118,000/MT, down from INR 130,000/MT. PKO remains strong at INR 215,000–230,000/MT, offering competitiveness with coconut oil—positive for margins.
- A refinery for PKO is being commissioned by the end of the season and is expected to add 1–2% to margins. Fresh Fruit Bunch (FFB) arrivals were subdued in FY25 due to water and monsoon distribution issues but grew 10% YoY in 4Q.
- FY26 FFB arrivals are expected to grow ~18%, with April off to a strong start. Profit growth is expected to mirror volume growth in FY26.

Poultry

- Product mix for FY25 comprised of Live Bird (32%) and Yumiezz and RGC combined (68%)
- Live Bird's revenue contribution declined to 23% in FY25 from 39% in FY24. The reduced focus on live birds - given their high price volatility, has proven beneficial
- Although 4QFY25 witnessed high live bird prices, such levels are not expected to be sustained. The business environment is expected to stabilize over the next 1–2 quarters.

Animal Feed

- The Aqua feed business is expected to witness strong growth. FY25 benefited from soft raw material prices, resulting in margin expansion.
- The ethanol blending policy indirectly lowered input costs (e.g., soybean), supporting margins.
- EBIT per kg is expected to be maintained at ~INR 1.9–2/kg in FY26 (with some quarterly fluctuations).

Others

- The company has moved away from the supplier financing arrangements, as the spread was quite high, leading to a reduction in payables days. Backed by a reduction in inventory, the working capital cycle improved.
- FY25 working capital levels are considered sustainable.
- Capex will be directed only toward high-margin businesses, such as Vegetable Oil.

Valuation and view

- GOAGRO reported flat revenue growth in FY25, but margins expanded 140bp due to strategic initiatives by the management. Going forward, with an improving outlook for Astec and volume-led growth in CP standalone, AF, and palm oil, we expect the company to see healthy revenue growth in the near term. Margins are anticipated to further expand going forward, fueled by continued strategic interventions across segments and recovery in Astec.
- We expect a revenue/EBITDA/Adj. PAT CAGR of 13%/22%/30% over FY25-27. **We reiterate our BUY rating on the stock with an SOTP-based TP of INR840.**

Exhibit 11: Valuations

Particulars	FY27 EBITDA	EV/ EBITDA (x)	EV (INRm)	Net Debt (INRm)	Equity Value (INRm)	GOAGRO's share (%)	Value (INRm)	Value/ share (INR)	% Share
Standalone:									
Crop Protection	3,799	12	45,589		45,589	100%	45,589	237	28%
Palm Oil	3,611	12	43,328		43,328	100%	43,328	226	27%
Animal Feed	4,359	13	57,101		57,101	100%	57,101	297	35%
Unallocated expenses	-2,149	10	-21,490		-21,490	100%	-21,490	-112	-13%
Total	9,619	13	1,24,527	19,708	1,04,819	100%	1,04,819	546	65%
Subsidiaries:									
Astec (mcap with 20% holdco disc)					10,571	65%	6,846	36	4%
Creamline Dairy	1397	12	16,760	-196	16,956	100%	16,956	88	11%
Godrej Tyson Foods Limited & Others	1073	14	15,023		15,023	100%	15,023	78	9%
JV/ Associate:									
ACI Godrej Agrovet Private Limited	2,366	15	35,484		35,484	50%	17,742	92	11%
Total	14,455	13	1,91,793		1,82,853			840	100%

Source: MOFSL

Exhibit 12: Revisions to our estimates

Earnings Change (INR m)	Old		New		Change	
	FY26E	FY27E	FY26E	FY27E	FY26E	FY27E
Revenue	1,07,544	1,17,908	1,08,976	1,19,389	1%	1%
EBITDA	10,821	12,262	9,962	12,103	-8%	-1%
Adj. PAT	6,295	7,291	5,656	7,217	-10%	-1%

Source: MOFSL

Financials and valuations

Consolidated - Income Statement									(INR m)
Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Total Income from Operations	59,177	68,294	62,667	83,061	93,737	95,606	93,828	1,08,976	1,19,389
Change (%)	13.7	15.4	-8.2	32.5	12.9	2.0	-1.9	16.1	9.6
Raw Materials	45,736	53,194	46,078	63,048	73,891	72,437	69,462	80,097	87,274
Employees Cost	2,944	3,541	3,764	4,393	4,534	5,391	5,347	5,994	6,387
Other Expenses	5,939	7,454	7,187	8,966	10,084	10,763	10,857	12,923	13,625
Total Expenditure	54,619	64,189	57,029	76,407	88,509	88,591	85,666	99,014	1,07,286
% of Sales	92.3	94.0	91.0	92.0	94.4	92.7	91.3	90.9	89.9
EBITDA	4,558	4,104	5,638	6,654	5,228	7,015	8,162	9,962	12,103
Margin (%)	7.7	6.0	9.0	8.0	5.6	7.3	8.7	9.1	10.1
Depreciation	982	1,481	1,540	1,733	1,855	2,143	2,261	2,595	2,707
EBIT	3,577	2,624	4,098	4,921	3,373	4,872	5,901	7,367	9,396
Int. and Finance Charges	339	416	465	631	991	1,079	1,334	1,409	1,454
Other Income	531	468	396	797	367	413	435	479	525
PBT bef. EO Exp.	3,769	2,675	4,029	5,086	2,749	4,206	5,002	6,438	8,467
EO Items	883	682	0	-173	708	0	0	0	0
PBT after EO Exp.	4,652	3,357	4,029	4,914	3,457	4,206	5,002	6,438	8,467
Total Tax	1,280	481	1,055	1,224	823	1,133	1,504	1,620	2,131
Tax Rate (%)	27.5	14.3	26.20	24.91	23.81	26.93	30.1	25.2	25.2
Profit from Associate & MI	82	-185	-164	-337	-385	-523	-799	-839	-881
Reported PAT	3,290	3,062	3,137	4,026	3,019	3,596	4,297	5,656	7,217
Adjusted PAT	2,407	2,510	3,137	4,154	2,495	3,596	4,297	5,656	7,217
Change (%)	10.9	4.3	25.0	32.4	-39.9	44.1	19.5	31.6	27.6
Margin (%)	4.1	3.7	5.0	5.0	2.7	3.8	4.6	5.2	6.0

Consolidated - Balance Sheet									(INR m)
Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Equity Share Capital	1,920	1,920	1,921	1,921	1,922	1,922	1,922	1,922	1,922
Total Reserves	14,570	16,461	18,590	20,763	21,454	23,244	21,886	16,226	23,443
Net Worth	16,490	18,381	20,511	22,684	23,375	25,167	23,808	18,148	25,365
Minority Interest	4,010	3,825	4,103	4,203	4,061	4,045	2,216	1,939	1,649
Total Loans	3,950	6,185	9,428	15,660	13,215	13,085	13,672	20,672	15,672
Deferred Tax Liabilities	2,086	1,751	1,713	1,559	1,798	1,679	1,433	1,433	1,433
Capital Employed	26,536	30,142	35,755	44,105	42,449	43,975	41,130	42,193	44,120
Gross Block	21,246	23,812	26,551	29,372	30,520	34,717	39,206	40,625	42,669
Less: Accum. Deprn.	3,196	4,677	6,217	7,950	9,805	11,948	14,209	16,803	19,510
Net Fixed Assets	18,050	19,136	20,334	21,422	20,715	22,770	24,998	23,822	23,159
Goodwill on Consolidation	2,649	2,649	2,649	2,649	2,649	2,649	2,649	2,649	2,649
Capital WIP	936	1,532	1,414	902	2,044	1,915	399	1,180	1,336
Total Investments	1,165	1,292	1,237	1,597	1,584	1,766	1,386	1,386	1,386
Curr. Assets, Loans&Adv.	19,542	22,392	22,355	29,271	27,867	27,933	25,727	28,971	32,802
Inventory	9,517	9,436	10,419	14,288	13,441	13,830	12,587	14,649	15,872
Account Receivables	7,349	8,539	8,226	9,514	5,740	5,189	5,721	5,971	6,542
Cash and Bank Balance	299	508	509	347	295	529	393	723	1,433
Loans and Advances	2,378	3,910	3,200	5,123	8,390	8,385	7,026	7,628	8,954
Curr. Liability & Prov.	15,807	16,859	12,235	11,735	12,411	13,058	14,029	15,815	17,212
Account Payables	12,394	12,885	7,326	6,948	7,043	6,278	8,855	9,494	10,288
Other Current Liabilities	2,934	3,467	4,206	3,384	4,459	6,020	4,754	5,449	5,969
Provisions	478	507	703	1,403	909	760	421	872	955
Net Current Assets	3,736	5,533	10,120	17,536	15,456	14,875	11,698	13,156	15,590
Appl. of Funds	26,536	30,142	35,755	44,105	42,449	43,975	41,130	42,193	44,120

Financials and valuations

Ratios

Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Basic (INR)									
EPS	12.5	13.1	16.3	21.6	13.0	18.7	22.4	29.5	37.6
Cash EPS	17.6	20.8	24.4	30.7	22.7	29.9	34.2	43.0	51.7
BV/Share	85.9	95.7	106.8	118.1	121.7	131.1	124.0	94.5	132.1
DPS	4.5	5.5	8.0	9.5	9.5	10.0	10.5	10.5	0.0
Payout (%)	31.6	41.5	49.0	45.3	60.4	53.4	46.9	35.6	0.0
Valuation (x)									
P/E	53.2	51.0	40.8	30.8	51.3	35.6	29.8	22.6	17.7
Cash P/E	37.8	32.1	27.4	21.8	29.4	22.3	19.5	15.5	12.9
P/BV	7.8	7.0	6.2	5.6	5.5	5.1	5.4	7.1	5.0
EV/Sales	2.3	2.0	2.3	1.8	1.5	1.5	1.5	1.4	1.2
EV/EBITDA	29.8	33.5	25.0	22.2	27.7	20.6	17.6	15.1	11.9
Dividend Yield (%)	0.7	0.8	1.2	1.4	1.4	1.5	1.6	1.6	0.0
FCF per share	9.0	-1.2	-13.1	-20.2	33.6	14.1	39.5	24.7	30.0
Return Ratios (%)									
RoE	15.7	14.4	16.1	19.2	10.8	14.8	17.5	27.0	33.2
RoCE	15.4	11.8	12.2	12.6	7.6	10.3	11.7	15.4	18.6
RoIC	12.2	8.8	10.2	10.0	6.4	9.1	10.5	14.2	17.8
Working Capital Ratios									
Fixed Asset Turnover (x)	2.8	2.9	2.4	2.8	3.1	2.8	2.4	2.7	2.8
Asset Turnover (x)	2.2	2.3	1.8	1.9	2.2	2.2	2.3	2.6	2.7
Inventory (Days)	59	50	61	63	52	53	49	49	49
Debtor (Days)	45	46	48	42	22	20	22	20	20
Creditor (Days)	76	69	43	31	27	24	34	32	31
Leverage Ratio (x)									
Current Ratio	1.2	1.3	1.8	2.5	2.2	2.1	1.8	1.8	1.9
Interest Cover Ratio	10.6	6.3	8.8	7.8	3.4	4.5	4.4	5.2	6.5
Net Debt/Equity	0.2	0.3	0.4	0.7	0.6	0.5	0.6	1.1	0.6

Consolidated - Cash Flow Statement

(INR m)

Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
OP/(Loss) before Tax	4,773	3,486	4,531	5,416	2,749	4,206	5,538	6,438	8,467
Depreciation	982	1,481	1,540	1,733	1,855	2,143	2,261	2,595	2,707
Interest & Finance Charges	339	416	465	631	624	666	1,334	930	929
Direct Taxes Paid	-1,097	-969	-1,123	-1,533	-823	-1,237	-1,465	-1,620	-2,131
(Inc)/Dec in WC	633	-2,204	-5,413	-7,085	4,335	812	2,569	-1,405	-2,014
CF from Operations	5,629	2,210	0	-838	8,740	6,590	10,236	6,936	7,958
Others	-1,152	188	-104	-362	0	190	-542	0	0
CF from Operating incl EO	4,477	2,398	-104	-1,201	8,740	6,780	9,693	6,936	7,958
(Inc)/Dec in FA	-2,759	-2,634	-2,406	-2,680	-2,290	-4,068	-2,116	-2,200	-2,200
Free Cash Flow	1,719	-236	-2,510	-3,880	6,449	2,712	7,577	4,736	5,758
(Pur)/Sale of Investments	0	0	-9	-166	12	-182	232	-9,300	0
Others	386	82	627	765	-564	976	1,069	1,042	1,115
CF from Investments	-2,372	-2,552	-1,787	-2,081	-2,842	-3,273	-815	-10,458	-1,085
Issue of Shares	0	0	0	0	1	1	1	0	0
Inc/(Dec) in Debt	-680	2,311	3,579	5,778	-2,445	-130	-274	7,000	-5,000
Interest Paid	-354	-390	-430	-602	-991	-1,079	-1,219	-1,409	-1,454
Dividend Paid	-1,076	-1,076	-1,122	-1,591	-1,824	-1,920	-1,923	-2,016	0
Others	4	-481	-136	-478	-689	-145	-5,598	277	291
CF from Fin. Activity	-2,105	364	1,891	3,108	-5,949	-3,273	-9,013	3,852	-6,163
Inc/Dec of Cash	0	210	-1	-173	-51	233	-135	330	710
Opening Balance	299	299	510	509	347	296	529	393	723
Closing Balance	299	508	509	347	296	529	393	723	1,433

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>. MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal Capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal Capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interest pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets Singapore Pte Ltd ("MOCMSPL") (Co. Reg. NO. 201129401Z) which is a holder of a capital markets services license and an exempt financial adviser in Singapore. As per the approved agreement under Paragraph 9 of Third Schedule of Securities and Futures Act (CAP 289) and Paragraph 11 of First Schedule of Financial Advisors Act (CAP 110) provided to MOCMSPL by Monetary Authority of Singapore. Persons in Singapore should contact MOCMSPL in respect of any matter arising from, or in connection with this report/publication/communication. This report is distributed solely to persons who qualify as "Institutional Investors", of which some of whom may consist of "accredited" institutional investors as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore ("the SFA"). Accordingly, if a Singapore person is not or ceases to be such an institutional investor, such Singapore Person must immediately discontinue any use of this Report and inform MOCMSPL.

Specific Disclosures

- 1 MOFSL, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- 2 MOFSL, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company
- 3 MOFSL, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months
- 4 MOFSL, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report
- 5 Research Analyst has not served as director/officer/employee in the subject company
- 6 MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- 7 MOFSL has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- 8 MOFSL has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months
- 9 MOFSL has not received any compensation or other benefits from third party in connection with the research report
- 10 MOFSL has not engaged in market making activity for the subject company

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report. Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no warranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alterations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN.: 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrivances@motilaloswal.com.